Drug
Erlotinib clinical trials
Also written Tarceva, OSI-774 and CP-358,774.
- studies test it
- 574
- open now
- 10
- in phase 3
- 52
- first study started
- 2001
Keep track of what changes. Save the erlotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
571 studies that test it; most in 2006 (70); 1 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 10 |
| 2002 | 25 |
| 2003 | 21 |
| 2004 | 29 |
| 2005 | 43 |
| 2006 | 70 |
| 2007 | 69 |
| 2008 | 62 |
| 2009 | 56 |
| 2010 | 35 |
| 2011 | 37 |
| 2012 | 24 |
| 2013 | 21 |
| 2014 | 23 |
| 2015 | 14 |
| 2016 | 10 |
| 2017 | 8 |
| 2018 | 3 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 188
- Phase 2
- 370
- Phase 3
- 52
- Phase 4
- 12
- No phase
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 120 · Other 454
National Cancer Institute (NCI) (64) · Hoffmann-La Roche (41) · M.D. Anderson Cancer Center (37) · OSI Pharmaceuticals (11) · Genentech, Inc. (11) · SCRI Development Innovations, LLC (11) · Eli Lilly and Company (10) · Vanderbilt-Ingram Cancer Center (10)
Often tested with
Tested in the same studies.
Bevacizumab (72) · Gemcitabine (43) · Docetaxel (31) · Cisplatin (21) · Carboplatin (20) · Paclitaxel (20) · Pemetrexed (20) · Capecitabine (19)
Studies
Open first, then newest update. How each study uses erlotinib is read from its arms, and is right about nine times in ten.
Testing it · 574
- Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingPhase 2Mayo ClinicNCT06997068Written as Erlotinib Hydrochloride
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingPhase 2National Cancer Institute (NCI)NCT04981509Written as Erlotinib
- Epidermal Growth Factor Receptor Inhibition for KeratinopathiesNot yet recruitingPhase 1/2Northwestern UniversityNCT06545695Written as Erlotinib
- Erlotinib for Hepatocellular Carcinoma ChemopreventionNot yet recruitingPhase 2University of Texas Southwestern Medical CenterNCT04172779Written as erlotinib hydrochloride
- Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingPhase 1/2UNC Lineberger Comprehensive Cancer CenterNCT06483555Written as Erlotinib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Erlotinib
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Erlotinib
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013Written as Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Erlotinib
- A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerRecruitingPhase 2Asan Medical CenterNCT05904457Written as erlotinib
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNot applicableNational Cancer Institute (NCI)NCT02194738Written as Erlotinib
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingPhase 3Eli Lilly and CompanyNCT02411448Written as Erlotinib
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01708954Written as Erlotinib Hydrochloride
- Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid TumorsCompletedPhase 1Alaunos TherapeuticsNCT00591383Written as erlotinib
- Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid CarcinomaCompletedNot applicableInstitut Claudius RegaudNCT00144976Written as Tarceva
- Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung CancerCompletedPhase 2University Hospital, LimogesNCT01350817Written as Erlotinib + docetaxel
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01660971Written as Erlotinib Hydrochloride
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00878163Written as Erlotinib Hydrochloride
- Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.CompletedPhase 3ETOP IBCSG Partners FoundationNCT01652469Written as Erlotinib
- BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)CompletedPhase 2ETOP IBCSG Partners FoundationNCT01562028Written as Erlotinib
See all 574 studies that test erlotinib →
Given in every arm · 93 — erlotinib is usual care beside what is tested
- To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 2OBI Pharma, IncNCT05442060Written as Erlotinib (150 mg daily)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingPhase 1Genentech, Inc.NCT04449874Written as Erlotinib
- Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsTerminatedPhase 1Boundless Bio, Inc.NCT05827614Written as Erlotinib
- Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingPhase 2NRG OncologyNCT03137771Written as Erlotinib Hydrochloride
- A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedPhase 1AstraZenecaNCT00600496Written as Erlotinib
- Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR MutationsCompletedPhase 3Guangdong Association of Clinical TrialsNCT02759614Written as Erlotinib
- A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsCompletedPhase 2Eli Lilly and CompanyNCT01897480Written as Erlotinib
- Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyCompletedPhase 2Astellas Pharma IncNCT01186861Written as erlotinib
- Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) GeneCompletedPhase 2Astellas Pharma IncNCT01221077Written as Erlotinib
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) MutationsActive, not recruitingPhase 2Massachusetts General HospitalNCT00977470Written as Erlotinib
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1AbbVieNCT02099058Written as Erlotinib
- Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsWithdrawnPhase 1National Cancer Institute (NCI)NCT06161558Written as Erlotinib
- Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic CancerCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT00954525Written as Gemcitabine and Erlotinib
- MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous ChemotherapyCompletedPhase 1/2NCIC Clinical Trials GroupNCT01068587Written as erlotinib hydrochloride
- EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant GliomasCompletedPhase 1Andrew B Lassman, MDNCT01257594Written as erlotinib
- Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerStatus unknownPhase 3National Cancer Institute, NaplesNCT02633189Written as Erlotinib
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT02039674Written as Erlotinib
- Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLCCompletedPhase 1/2Syndax PharmaceuticalsNCT00602030Written as Erlotinib
- S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedPhase 1/2National Cancer Institute (NCI)NCT00617708Written as erlotinib hydrochloride
- A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationTerminatedPhase 1/2Eli Lilly and CompanyNCT04165031Written as Erlotinib
Showing 20 of 93.
As the comparator · 15 — what is tested is compared with erlotinib
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT04455594Written as Erlotinib
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT02152631Written as Erlotinib
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesCompletedPhase 2/3Alpha Biopharma (Jiangsu) Co., Ltd.NCT03653546Written as Erlotinib
- A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedPhase 3Astellas Pharma Global Development, Inc.NCT02588261Written as Erlotinib
- A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedPhase 3AstraZenecaNCT02352948Written as Erlotinib
- KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyTerminatedPhase 3Kadmon Corporation, LLCNCT01487174Written as Erlotinib
- Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00606502Written as Erlotinib
- Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With ChemotherapyCompletedPhase 1Novartis PharmaceuticalsNCT00456833Written as erlotinib
- LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyCompletedPhase 3Boehringer IngelheimNCT01523587Written as erlotinib
- A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)CompletedPhase 2Merck Sharp & Dohme LLCNCT00654420Written as Erlotinib
- Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior ChemotherapyCompletedPhase 3Genzyme, a Sanofi CompanyNCT00364351Written as Erlotinib
- ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerCompletedPhase 3PfizerNCT01360554Written as Active Comparator (erlotinib)
- A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCCompletedPhase 2Bristol-Myers SquibbNCT00743938Written as Erlotinib
- A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenCompletedPhase 2PfizerNCT00769067Written as Erlotinib
- SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)CompletedPhase 2Merck Sharp & Dohme LLCNCT00732810Written as Erlotinib
Codes
What other systems call erlotinib · ClinicalTrials.gg INT006571
- MeSH (NLM) D000069347Erlotinib HydrochlorideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) J4T82NDH7EERLOTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 337525Confirmed FDA, Wikidata
- Wikidata Q418369erlotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65530ErlotinibOne source FDA
- DrugBank DB00530One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069347 | Erlotinib Hydrochloride | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | J4T82NDH7E | ERLOTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 337525 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418369 | erlotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65530 | Erlotinib | One source FDA |
| DrugBank | DB00530 | — | One source Wikidata |
Also registered as erlotinib hydrochloride (UNII DA87705X9K · RxNorm 477320).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.